Xu Zhang Jiabin Zheng Yun Niu Chongxiang Xue Yixuan Yu Kexin Tan Huijuan Cui
10.3389/fimmu.2022.1059331
Front Immunol
2022 Nov 30;13:1059331.
es-sclc icis combined regimens long-term survival re-challenge
CC BY
https://pubmed.ncbi.nlm.nih.gov/36532013/
Lung Neoplasms / pathology Small Cell Lung Carcinoma / drug therapy Small Cell Lung Carcinoma / pathology
Lung Neoplasms / pathology Small Cell Lung Carcinoma / drug therapy Small Cell Lung Carcinoma / pathology Review Case Reports Research Support, Non-U.S. Gov't Disease Progression Humans Immune Checkpoint Inhibitors / therapeutic use Immunotherapy Middle Aged Immune Checkpoint Inhibitors
PMC9747940
36532013
Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review
2022